Shares of PEIJIA-B (09996) showed strong momentum during the morning session on August 24, climbing more than 8%. The company recently released its interim results, which highlighted robust key metrics, with revenue reaching RMB 425 million, up 20.1% year-on-year, and gross profit hitting RMB 290 million, a 17.13% increase. Through a steady strategic roadmap and solid clinical achievements, the company underscored its long-term investment appeal amid a volatile market landscape.

By continuously refining its product mix, implementing lean cost management measures, and boosting operational efficiency, the company managed to offset headwinds from TAVR price adjustments, higher initial manufacturing costs during the ramp-up of TaurusTrio®, and the impact of centralized procurement in its neurointerventional business, all while sustaining a stable gross margin of approximately 68.3%. Notably, driven by strong momentum in the first half, the company has raised its full-year TAVR implantation guidance to 6,000–6,500 units.

In its transcatheter valve therapy segment, the company continues to cement its leading position in China's transfemoral TAVR market. As of June 30, 2026, its TAVR product portfolio had expanded hospital coverage to over 850 facilities across the Greater China region, adding roughly 70 hospitals compared to December 31, 2025. During the reporting period, total TAVR implantations, including products for aortic stenosis and AR indications, reached approximately 2,830 units, marking a significant 36.5% increase in volume compared to the six months ended June 30, 2025.

Overall, despite a challenging industry environment, the company not only achieved dual improvements in revenue and profitability but also raised its sales outlook against the grain, thanks to its differentiated product pipeline—underscoring the strength of its competitive moat. As its dual-engine strategy of neurointervention and valve therapy solidifies, the current positive market reaction may only mark the beginning of a value re-rating, with further upside potential tied to the realization of its pipeline milestones.